Trial Profile
A Multicenter Phase II Study Incorporating DOXIL [doxorubicin liposomal] and Rituximab Into the Magrath [vincristine, cyclophosphamide, methotrexate, cytarabine, ifosfamide, etoposide] Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2019
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Cyclophosphamide; Cytarabine; Etoposide; Ifosfamide; Methotrexate; Rituximab; Vincristine
- Indications Burkitt's lymphoma
- Focus Therapeutic Use
- 24 Sep 2019 Status changed from active, no longer recruiting to completed.
- 05 Apr 2019 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 05 Apr 2019 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.